With new CEO on board, Germany's Vibalogics lays out $150M for Boston viral vector site

[cafead]

via With the race for COVID-19 vaccines heating up and the cell and gene therapy market booming, contract manufacturers in the viral vector space are quickly bulking up to meet demand. Hoping to ride that wave, Germany's Vibalogics is planting its flag in the U.S. with a new leader in place.

article source